GSK invests $270M into vaccine manufacturing in Belgium
GSK is investing about $270 million (€250 million) to build out and expand its vaccine manufacturing facilities in Wavre, Belgium.
The plant is expected to have two wings: one for producing its “non-live” vaccines, including the newly approved RSV vaccine Arexvy and the shingles vaccine Shingrix, and the other wing will make “live” vaccines, including Varilrix for chickenpox and Priorix for measles.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.